Ali Khojasteh
Hematology & Oncology · Jefferson City, MONPI 1467411488
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Tesaro, Inc. accounts for 72.5% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $7,262 and has fallen 97.2% since, to $200 in 2023.
Across 123 payments — averaging $64.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tesaro, Inc.$6K
- Novartis$459
- Johnson & Johnson$274
- Daiichi Sankyo Inc.$264
- Pfizer$256
- Incyte Corporation$202
- plus $737 from 19 others
Across 5 payments — averaging $5158.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$20K
- Genentech, Inc.$5K
- Incyte Corporation$54
What the payments were for
- Consulting fees$4,68059%
- Speaking & faculty fees$2003%
- Travel & lodging$87011%
- Food & beverage$2,00525%
- Education$2213%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tesaro, Inc. | 9 | $5,784 |
| Novartis | 27 | $459 |
| Johnson & Johnson | 15 | $274 |
| Daiichi Sankyo Inc. | 5 | $264 |
| Pfizer | 18 | $256 |
| Incyte Corporation | 8 | $202 |
| Gilead | 7 | $103 |
| Boehringer Ingelheim | 4 | $78 |
| AstraZeneca | 5 | $74 |
| Lilly USA, LLC | 3 | $60 |
| Sanofi | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Abbott | 1 | $54 |
| Amgen | 3 | $50 |
| Bristol Myers Squibb | 2 | $34 |
| Taiho Oncology, Inc. | 1 | $22 |
| Array Biopharma Inc | 1 | $21 |
| Bayer | 1 | $19 |
| Dendreon Pharmaceuticals LLC | 1 | $18 |
| Merck | 1 | $17 |
| Seagen Inc. | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $15 |
| Blueprint Medicines Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEJULA$5,644
How this compares
$7,976 in reported general payments places this provider in the 75th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Jefferson City
- Shadi HaddadinJefferson City$62K
- Tamara HopkinsJefferson City$6K
- David SchlossmanColumbia$1.2M
- Mark FeslerSaint Louis$870K
- Kelly PendergrassLees Summit$189K
- Jonathan MizrahiSaint Louis$188K
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Muhammad MirzaWashington$65K
- Yifan TuSt. Louis$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.